Asmacure closes US$9 million Series A financing

On May 8, 2007, Asmacure Ltée announced that it had closed a Series A round of financing of US$9 million utilizing an exchangeable shares structure involving Fonds Bio-Innovation and Innovatech Québec Chaudière-Appalaches from Québec City, and Domain Associates from Princeton, New Jersey. This investment will support Asmacure's operations and R & D program through the preclinical and initial clinical development of its Lead Compound aimed at a new pharmacological approach for the treatment of asthma. Asmacure was advised in this financing by a team from Fasken Martineau led by François Duchesneau and that included, among others, René Roy, Marie Carole Tétrault and Jean-Gabriel L'Ecuyer in Québec City and Martin Fisher-Haydis in Toronto.